Compass Therapeutics (CMPX) Stock Forecast & Price Target

Compass Therapeutics Inc. is advancing its proprietary antibody therapeutics aimed at engaging the immune system to combat solid tumors and hematological malignancies, with promising data indicating improved response rates over standard therapies in colorectal cancer and other indications. The company has expanded its drug pipeline with clinical prospects such as CTX-8371, which presents a differentiated safety profile and multi-indication activity, bolstering its potential market reach, particularly in NSCLC and TNBC. Despite a 49% increase in R&D expenses, reflecting investment in innovation, the decline in G&A expenses indicates effective cost management, positioning Compass Therapeutics for potential growth, especially if clinical trials yield statistically significant results leading to accelerated regulatory approvals.

Compass Therapeutics Inc. has reported a worsening financial situation, displaying a net loss of $14.3 million in Q3 2025, an increase from the $10.5 million loss in Q3 2024, primarily driven by elevated R&D investments for CTX-10726. The company's clinical developments have faced significant challenges, including the failure of the VEGF/DLL4 bispecific dilpacimab in colorectal cancer due to poor tolerability and efficacy, as demonstrated by adverse outcomes including a death from gastrointestinal perforation. Furthermore, the uncertainty about overall survival due to limited data points—resulting in a 40-50% probability of success—raises considerable concerns about the viability of its therapeutic pipeline and could negatively affect investor confidence.